에볼루션 바카라 achieves consecutive Phase 2 success in endometriosis and uterine fibroids… Boosting expectations for follow-up development
[by Ji, Yong Jun] Tiumbio, a company specializing in research and development of rare and intractable disease treatments, announced on June 25 its upcoming participation in the 2025 European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting. During the event, the company will present clinical data and explore the potential development of 에볼루션 바카라 (development code: TU2670), a treatment candidate for endometriosis and uterine fibroids.
The 2025 ESHRE Annual Meeting will be held in Paris, France, from June 29 to July 2. ESHRE is recognized as one of the most prestigious international academic societies in the field of reproductive medicine alongside the American Society for Reproductive Medicine (ASRM).
Tiumbio is set to present the results of its European Phase 2a clinical trial of Merigolix for endometriosis during a session titled ‘Breaking Boundaries in Endometriosis: From the Microbiome to Maternal Outcomes,’ highlighting new approaches and treatments in endometriosis research. The presentation will be delivered by Dr. Krzysztof Szymanowski, the study’s principal investigator (PI) based in Poland.
Merigolix, the investigational treatment for endometriosis and uterine fibroids to be presented by Dr. Szymanowski to leading academic and industry figures, has demonstrated efficacy and safety by meeting the primary endpoint in Phase 2 clinical trials conducted for both indications. Notably, the high-dose cohort exhibited dose-dependent therapeutic effects, further supporting Merigolix’s mechanism of action and reinforcing its potential as a viable treatment option.
In addition, 에볼루션 바카라 has secured positive outcomes in key secondary endpoints. In the endometriosis clinical trial, it demonstrated improvement in nonmenstrual pelvic pain (NMPP), while in the uterine fibroid trial, it led to increased hemoglobin levels and a reduction in fibroid size. It has also proven overall safety and tolerability.
“It is meaningful to have the opportunity to directly share the clinical performance and therapeutic potential of Merigolix with globally renowned scholars at this conference,” said Kim Hun-taek, CEO of Tiumbio. “With positive clinical outcomes secured in both indications, endometriosis and uterine fibroids, the value of Merigolix as a novel drug has been further increased,” he added.